Seeking Alpha
17 Nov 2026, 07:47 UTC · 5h ago
Electra Therapeutics: A Broken IPO Leaves The SIRP Platform Nearly Free
Impact · against what's priced in
Electra Therapeutics presents a high-asymmetry bet where the current enterprise value is low relative to its cash position and pipeline. While the early sHLH efficacy is strong, the stock's upside depends on the SURPASS pivotal readout and regulatory acceptance of its comparator, rather than the already known cash runway.
- ETRA+0.50
No priced-in read yet
- In context
The company has a cash runway into 2029 and promising early data showing 100% eight-week survival in sHLH patients, suggesting the current enterprise value may undervalue the SIRP platform.
Read from the article alone





